Diabetic Retinopathy

Sponsored by: GlobalData

Focused on:

  • Global Drug Forecast

Date: 20 October


Time: 3PM London / 10AM New York

Global Drug Forecast and Market Analysis to 2029

Diabetic retinopathy (DR) is a sight-threatening microvascular eye complication of type 1 and type 2 diabetes. The disease is also the leading cause of preventable visual disability and blindness in working-age adults throughout the world. An estimated 60% of diabetics will develop some form of DR within 20 years of developing diabetes. Despite the fact that the disease has a seriously negative impact on patients’ quality of life, there are few recognizable symptoms until the onset of vision loss. The two major types of DR are non-proliferative diabetic retinopathy (NPDR) which is characterized by damage to existing blood vessels in the retina, and proliferative diabetic retinopathy (PDR), which is when new blood vessels grow in the retina, which can lead to the obstruction of ocular structures. New blood vessels can press on retinal veins, block blood flow, and cause a condition called retinal vein occlusion (RVO). Similarly, blood or fluid from these new blood vessels can leak on to the macula, which is the part of the retina that controls our central vision and ability to see fine details. The buildup of blood or fluid in the region of the macula is known as diabetic macular edema (DME). It is DME that poses the greatest risk to sight. Treating DR at its earliest stages is one of the most important ways to stop the progression of the disease, delay vision loss, and reduce the negative impact of the disease on patients’ quality of life. In GlobalData’s expert presentation “Diabetic Retinopathy: Global Drug Forecast and Market Analysis to 2029,” Senior Healthcare Analyst Maddy Crabbe explains why this market is expected to more than double in size between 2019 and 2029, and what opportunities exist for pharmaceutical companies to reap the benefits from investing in this therapy area. Maddy will discuss some of the unmet needs for patients with DR, RVO, and DME, examine the portfolios of some of the biopharmaceutical companies represented in the market and pipeline, and delve into the market drivers and barriers that exist across the nine major markets (US, France, Germany, Italy, Spain, UK, Japan, China, and Australia). In this webinar, Michael Breen, Director of Infectious Diseases and Ophthalmology will moderate the Q&A session after the presentation.

Presented by

Maddy Crabbe ,

Senior Healthcare Analyst - Ophthalmology

Maddy is a Senior Healthcare Analyst for the Ophthalmology team at GlobalData in London. She holds a BSc in Biochemistry and an MA in International Journalism from Cardiff University. She has worked in business intelligence since July 2018 and authored reports and news articles about medical breakthroughs in therapy areas such as neurology, immunology, ophthalmology, and otorhinolaryngology.

Michael Breen ,

Director, Infectious Diseases and Ophthalmology

Mike is the Director of Infectious Diseases and Ophthalmology at GlobalData in Boston. He has over seven years of experience in market analysis, business intelligence, and providing strategic insight for the pharmaceutical industry. Prior to his role at GlobalData, he was a Senior Analyst for Decision Resources Group, where he gained extensive experience writing in-depth reports and developing forecasts for a variety of indications, including rare and infectious diseases and vaccines.

Key Learning Objectives

  • Examine the key benefits and drawbacks of the market-leading therapies for DR, RVO, and DME
  • Understand to what extent the unmet needs will be addressed in this therapy area
  • Find out which pipeline products are expected to become top-selling therapies in 2029


  • Managers
  • Senior Managers
  • Associate Directors
  • Directors of Market Research
  • Business Insights
  • Market Intelligence
  • Strategic Insights
  • Forecasting
  • Pipeline Management
  • Competitive Strategy
  • Customer Insights
  • Heads of Research and Development
  • Heads of Product Planning and Marketing
  • Brand Managers